FDA Drug Recalls

436 recalls, newest first

Class II · Moderate risk Completed Mar 28, 2013

Levoxyl (levothyroxine sodium) tablets, USP 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count…

Reason Chemical contamination: emission of strong odor after package was opened.

Pfizer Inc. NDC 60793-858-01 D-259-2013

Class II · Moderate risk Completed Mar 28, 2013

Levoxyl (levothyroxine sodium) tablets, USP 137 mcg, packaged in a) 100-count bottles (NDC 60793-857-01) and b) 1000-count…

Reason Chemical contamination: emission of strong odor after package was opened.

Pfizer Inc. NDC 60793-857-01 D-258-2013

Class II · Moderate risk Completed Mar 28, 2013

Levoxyl (levothyroxine sodium) tablets, USP 125 mcg, packaged in a) 100-count bottles (NDC 60793-856-01) and b) 1000-count…

Reason Chemical contamination: emission of strong odor after package was opened

Pfizer Inc. NDC 60793-856-01 D-257-2013

Class II · Moderate risk Completed Mar 28, 2013

Levoxyl (levothyroxine sodium) tablets, USP 112 mcg, packaged in a) 100-count bottles (NDC 60793-855-01) and b) 1000-count…

Reason Chemical contamination: emission of strong odor after package was opened.

Pfizer Inc. NDC 60793-855-01 D-256-2013

Class II · Moderate risk Completed Mar 28, 2013

Levoxyl (levothyroxine sodium) tablets, USP 100 mcg, packaged in a) 100-count bottles (NDC 60793-854-01) and b) 1000-count…

Reason Chemical contamination: emission of strong odor after package was opened..

Pfizer Inc. NDC 60793-854-01 D-255-2013

Class II · Moderate risk Completed Mar 28, 2013

Levoxyl (levothyroxine sodium) tablets, USP 88 mcg, packaged in a) 100-count bottles (NDC 60793-853-01) and b) 1000-count bottles…

Reason Chemical contamination: emission of strong odor after package was opened..

Pfizer Inc. NDC 60793-853-01 D-254-2013

Class II · Moderate risk Completed Mar 28, 2013

Levoxyl (levothyroxine sodium) tablets, USP 75 mcg, packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count…

Reason Chemical contamination: emission of strong odor after package was opened.

Pfizer Inc. NDC 60793-852-01 D-253-2013

Class II · Moderate risk Completed Mar 28, 2013

Levoxyl (levothyroxine sodium) tablets, USP 50 mcg, packaged in a) 100-count bottles (NDC 60793-851-01) and b) 1000-count bottles…

Reason Chemical contamination: emission of strong odor after package was opened.

Pfizer Inc. NDC 60793-851-01 D-252-2013

Class II · Moderate risk Completed Mar 28, 2013

Levoxyl (levothyroxine sodium) tablets, USP 25 mcg, packaged in a) 100-count bottles (NDC 60793-850-01) and b) 1000-count bottles…

Reason Chemical contamination: emission of strong odor after package was opened..

Pfizer Inc. NDC 60793-850-01 D-251-2013

Class I · High risk Completed Nov 8, 2012

Carboplatin Injection, 450 mg/45 mL (10 mg/mL), 45 mL, Cytotoxic Agent, Sterile, Multi-Dose Vial, Rx only, For IV Use, NDC…

Reason Crystallization: Product is being recalled due to visible particulates identified during a retain sample inspection. Findings have identified the…

Hospira Inc. NDC 61703-339-50 D-154-2013

Class I · High risk Completed Nov 8, 2012

Carboplatin Injection, 600 mg/60 mL (10 mg/mL), 60 mL, Cytotoxic Agent, Sterile, Multi-Dose Vial, Rx only, For IV Use, Hospira…

Reason Crystallization: Product is being recalled due to visible particulates identified during a retain sample inspection. Findings have identified the…

Hospira Inc. NDC 61703-339-56 D-153-2013